AKT1 and B-cell chronic lymphocytic leukemia: Similar effects on N1-ICD and N1-TM were observed in CLL cells treated with the PI3Kδ inhibitor CAL-101 (idelalisib; n = 6; Supplementary Fig. S4), suggesting, in agreement with recent studies [49], that the PI3K/AKT pathway plays a critical role in sustaining N1-ICD in CLL.